Filter Results
:
(240)
Show Results For
-
All HBS Web
(637)
- Faculty Publications (240)
Show Results For
-
All HBS Web
(637)
- Faculty Publications (240)
- January 2006
- Case
Jack Strang at SequenceLabs
By: Mukti Khaire, John J. Gabarro and Lynda M. Applegate
How can entrepreneur manage his firm if things go wrong despite having a great idea, a solid team, and financial backing? Jack Strang founded a biotech firm with his friend Peter Evans, to develop molecular pathway-based "cures" for metabolic disorders. The idea was...
View Details
- December 2005 (Revised July 2006)
- Case
Bunge: Poised for Growth
By: David E. Bell and Mary L. Shelman
As CEO of the world's largest oilseed processor, Alberto Weisser of Bunge must not only decide how quickly to expand in fast-growing markets of Eastern Europe and Asia, but also how best to leverage the firm's global footprint and leadership position. The firm is...
View Details
Keywords:
Customer Focus and Relationships;
Trade;
Global Strategy;
Leadership;
Growth Management;
Management Style;
Demand and Consumers;
Supply Chain;
Integration;
Technology;
Biotechnology Industry;
Biotechnology Industry;
Asia;
Europe
Bell, David E., and Mary L. Shelman. "Bunge: Poised for Growth." Harvard Business School Case 506-036, December 2005. (Revised July 2006.)
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Biotechnology Industry;
Biotechnology Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- November 2005 (Revised November 2005)
- Case
Massachusetts General Hospital and the Enbrel Royalty
By: David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well...
View Details
Keywords:
Valuation;
Price;
Investment Return;
Capital;
Value;
Revenue;
Health Care and Treatment;
Biotechnology Industry;
Biotechnology Industry;
Massachusetts
Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised November 2005.)
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in...
View Details
Keywords:
Genetics;
Information Technology;
Business Model;
Disruptive Innovation;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- December 2004 (Revised July 2005)
- Case
Extend Fertility
By: Myra M. Hart and Sylvia Sensiper
Focuses on the search for opportunity, the generation and evaluation of business concepts, creation of a business plan, and the start-up process. Follows experienced entrepreneur Christy Jones as she combines her business skills and personal experience to generate new...
View Details
Keywords:
Opportunities;
Business Plan;
Entrepreneurship;
Personal Development and Career;
Social Issues;
Gender;
Business Startups;
Biotechnology Industry
Hart, Myra M., and Sylvia Sensiper. "Extend Fertility." Harvard Business School Case 805-065, December 2004. (Revised July 2005.)
- October 2004 (Revised March 2005)
- Case
Langer Lab, The: Commercializing Science
By: H. Kent Bowen, Alex Kazaks, Ayr Muir-Harmony and Bryce LaPierre
Professor Robert Langer's laboratory at MIT is the source of an unusually large number of published papers, patents, and technology licenses to start-up and established companies in the biomedical industry. Explores Langer's leadership and other factors that create a...
View Details
Keywords:
Entrepreneurship;
Technological Innovation;
Business Startups;
Research and Development;
Patents;
Innovation Leadership;
Science-Based Business;
Commercialization;
Biotechnology Industry;
Biotechnology Industry
Bowen, H. Kent, Alex Kazaks, Ayr Muir-Harmony, and Bryce LaPierre. "Langer Lab, The: Commercializing Science." Harvard Business School Case 605-017, October 2004. (Revised March 2005.)
- May 2004
- Teaching Note
Monsanto: Technology Cooperation and Small Holder Farmer Projects (TN)
By: James E. Austin and Diana Barrett
Teaching Note to (9-302-068).
View Details
Keywords:
Biotechnology Industry
- 2004
- Chapter
Genzyme's Gaucher Initiative: Global Risk and Responsibility
By: Christopher A. Bartlett and Andrew N. McLean
- December 2003 (Revised April 2004)
- Case
Dragon's Teeth Vineyards
By: Alan D. MacCormack, Marius Leibold, Sven Voelpel and Kerry Herman
Dragon's Teeth Vineyards (DTV) is a South African wine producer that is considering whether to use genetically modified organisms (GMOs) in its wine-making process. GMOs promise to lower the costs of wine production significantly through increased yields and reduced...
View Details
Keywords:
Technological Innovation;
Growth and Development Strategy;
Genetics;
Transition;
Brands and Branding;
Product Development;
Product Design;
Organizational Change and Adaptation;
Technology Adoption;
Biotechnology Industry;
Biotechnology Industry;
South Africa
MacCormack, Alan D., Marius Leibold, Sven Voelpel, and Kerry Herman. "Dragon's Teeth Vineyards." Harvard Business School Case 604-069, December 2003. (Revised April 2004.)
- September 2003 (Revised August 2005)
- Teaching Note
Calgene, Inc. (TN)
Teaching Note for (9-502-041)
View Details
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases.
View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases.
View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (D)." Harvard Business School Case 603-046, June 2003. (Revised October 2004.)
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations.
View Details
Keywords:
Health Disorders;
Research and Development;
Genetics;
Biotechnology Industry;
Biotechnology Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Biotechnology Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this...
View Details
Keywords:
Decision Making;
Moral Sensibility;
Innovation and Invention;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research and Development;
Biotechnology Industry;
Biotechnology Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
- Article
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By: Josh Lerner, Hilary Shane and Alexander Tsai
Lerner, Josh, Hilary Shane, and Alexander Tsai. "Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances." Journal of Financial Economics 67, no. 3 (March 2003): 411–446. (Earlier versions distributed as HBS Working Paper No. 00-038 and NBER Working Paper No. 7464.)
- February 2003
- Article
Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success
By: Ranjay Gulati and M. Higgins
This paper investigates the contingent value of interorganizational relationships at the time of a young firm's initial public offering (IPO). We compare the signaling value to young firms of having ties with two types of interorganizational partnerships: endorsement...
View Details
Keywords:
Interorganizatonal Relationships;
Networks;
Venture Capital;
Initial Public Offering;
Entrepreneurship;
Biotechnology Industry
Gulati, Ranjay, and M. Higgins. "Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success." Strategic Management Journal 24, no. 2 (February 2003): 127–144.
- Article
Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology
By: Rebecca M. Henderson, Sarah Kaplan and Fiona Murray
Henderson, Rebecca M., Sarah Kaplan, and Fiona Murray. "Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology." Industrial and Corporate Change 12, no. 2 (April 2003).
- November 2002 (Revised June 2003)
- Case
Monsanto: Leadership in a New Environment
By: Ray A. Goldberg, James Weber and James M Beagle
Monsanto is the biotechnology leader in agriculture. How does it use its leadership in Round Up to fund long-term research and development in biotechnology that is acceptable to the priority system of consumers in different parts of the world? Includes color exhibits.
View Details
Keywords:
Research and Development;
Science-Based Business;
Food;
Business or Company Management;
Agribusiness;
Industry Growth;
Customer Focus and Relationships;
Globalization;
Leadership;
Biotechnology Industry;
Biotechnology Industry;
United States
Goldberg, Ray A., James Weber, and James M Beagle. "Monsanto: Leadership in a New Environment." Harvard Business School Case 903-419, November 2002. (Revised June 2003.)